Page last updated: 2024-12-06

dinitramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dinitramine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34468
CHEMBL ID1223066
CHEBI ID81959
SCHEMBL ID66368
MeSH IDM0042513

Synonyms (60)

Synonym
CHEMBL1223066
chebi:81959 ,
dinitramine [ansi:bsi:iso]
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine
cobex (herbicide)
1,3-benzenediamine, n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-
n3,n3-diethyl-2,4-dinitro-6-trifluoromethyl-m-phenylenediamine
3-diethylamino-2,4-dinitro-6-trifluoromethylaniline
hsdb 6617
ai3-62693
epa pesticide chemical code 102301
n(3),n(3)-diethyl-2,4-dinitro-6-trifluoromethyl-m-phenylenediamine
n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)-1,3-benzenediamine
n4,n4-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine
caswell no. 335c
cobex
brn 2822138
1,3-benzenediamine, n(sup 3),n(sup 3)-diethyl-2,4-dinitro-6-(trifluoromethyl)-
n1,n1-diethyl-2,6-dinitro-4-trifluoromethyl-m-phenylenediamine
usb-3584
dinitramine
n(sup 3),n(sup 3)-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine
n,n-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine [iso]
toluene-2,4-diamine, n(sup 4),n(sup 4)-diethyl-3,5-dinitro-alpha,alpha,alpha-trifluoro-
n(sup 4),n(sup 4)-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine
cobeko
cobexo
einecs 249-419-2
toluene-2,4-diamine, n(sup 4),n(sup 4)-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitro-
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)benzene-1,3-diamine
n,n-diethyl-2,6-dinitro-4-(trifluoromethyl)benzene-1,3-diamine
3-n,3-n-diethyl-2,4-dinitro-6-(trifluoromethyl)benzene-1,3-diamine
usb 3584
29091-05-2
C18785
tox21_302221
cas-29091-05-2
NCGC00255511-01
dtxsid9040265 ,
dtxcid7020265
unii-xhq6d15979
1,3-benzenediamine, n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)-
n,n-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine
xhq6d15979 ,
FT-0630545
AKOS015888327
n(sup 1),n(sup 1)-diethyl-2,6-dinitro-4-trifluoromethyl-m-phenylenediamine
dinitramine [iso]
kobex
dinitramine [hsdb]
SCHEMBL66368
W-107007
toluene-2,4-diamine, n4,n4-diethyl-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitro-
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-phenylenediamine
toluene-2,4-diamine, n4,n4-diethyl-3,5-dinitro-.alpha.,.alpha.,.alpha.-trifluoro-
n4,n4-diethyl-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitrotoluene, 2,4-diamine
dinitramine, pestanal(r), analytical standard
cobex;n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine
n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)benzene-1,3-diamine
Q27155666

Research Excerpts

Overview

Dinitramine is a dinitroaniline herbicide that is particularly toxic to aquatic organisms.

ExcerptReferenceRelevance
"Dinitramine is a dinitroaniline herbicide that is particularly toxic to aquatic organisms."( Dinitramine induces implantation failure by cell cycle arrest and mitochondrial dysfunction in porcine trophectoderm and luminal epithelial cells.
An, G; Lim, W; Park, J; Song, G, 2022
)
2.89

Effects

ExcerptReferenceRelevance
"Dinitramine has an amine group at the meta position not present in any of the other dinitroanilines tested here that is predicted to form hydrogen bonds with residues Arg2 and Gln133 according to docking data."( Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
Gu, F; Li, C; Ma, C; Morrissette, N; Ochoa, R; Sept, D; Tran, J; Werbovetz, K, 2010
)
1.08
"Dinitramine has an amine group at the meta position not present in any of the other dinitroanilines tested here that is predicted to form hydrogen bonds with residues Arg2 and Gln133 according to docking data."( Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
Gu, F; Li, C; Ma, C; Morrissette, N; Ochoa, R; Sept, D; Tran, J; Werbovetz, K, 2010
)
1.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.30600.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency15.68920.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency42.65190.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.46010.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency44.33530.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency1.44930.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.10010.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency6.85900.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency47.64130.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743091
caspase-3Homo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.37620.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency13.68540.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency46.30370.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743067
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency34.37620.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency34.37620.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID522810Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522812Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522818Induction of parasite shape change Toxoplasma gondii RH infected in HFF cells at 0.25 uM by phase contrast microscopy2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522815Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522808Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522816Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522809Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522813Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522811Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522807Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522806Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID502117Antimicrobial activity against Toxoplasma gondii infected in HFF after 8 days by plaque assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of oryzalin analogs against Toxoplasma gondii.
AID522805Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522814Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522817Induction of parasite microtubule disruption Toxoplasma gondii RH infected in HFF cells by antitubulin antibody staining2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's1 (7.69)18.2507
2000's2 (15.38)29.6817
2010's2 (15.38)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.07 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]